Recent chatter on X about IGM Biosciences (IGMS) has been focused on the company’s ongoing developments in antibody therapeutics, particularly in the biotech sector. Many users are intrigued by the potential of IGMS's pipeline, with discussions often centering on the promise of their innovative approaches to treating complex diseases. The tone reflects curiosity about whether clinical milestones will translate into market success.
While some on the platform express optimism about the long-term prospects of IGMS, others raise concerns over the inherent risks of biotech investments, including regulatory hurdles and trial outcomes. This dichotomy keeps the conversation dynamic, as participants weigh the balance between groundbreaking science and financial uncertainty. The dialogue remains active, fueled by anticipation of upcoming data releases or partnership announcements.
Note: This discussion summary was generated from an AI condensation of post data.
IGM Biosciences Insider Trading Activity
IGM Biosciences insiders have traded $IGMS stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $IGMS stock by insiders over the last 6 months:
- MARY BETH HARLER (Chief Executive Officer) has made 0 purchases and 3 sales selling 23,352 shares for an estimated $29,296.
- MISBAH TAHIR (CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 17,592 shares for an estimated $21,965.
- LISA LYNN DECKER (CHIEF BUSINESS OFFICER) has made 0 purchases and 3 sales selling 9,872 shares for an estimated $12,301.
- STEVEN WEBER (PRINCIPAL ACCOUNTING OFFICER) has made 0 purchases and 3 sales selling 4,052 shares for an estimated $4,764.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IGM Biosciences Hedge Fund Activity
We have seen 35 institutional investors add shares of IGM Biosciences stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 3,526,135 shares (-98.8%) from their portfolio in Q1 2025, for an estimated $4,055,055
- FMR LLC removed 467,865 shares (-98.8%) from their portfolio in Q1 2025, for an estimated $538,044
- GSA CAPITAL PARTNERS LLP removed 425,303 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $476,339
- AQR CAPITAL MANAGEMENT LLC added 238,871 shares (+inf%) to their portfolio in Q1 2025, for an estimated $274,701
- GOLDMAN SACHS GROUP INC removed 185,099 shares (-18.9%) from their portfolio in Q1 2025, for an estimated $212,863
- TD ASSET MANAGEMENT INC removed 164,472 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $189,142
- RHENMAN & PARTNERS ASSET MANAGEMENT AB removed 126,064 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $144,973
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
